Condition
Malignant Pancreatic Neoplasm
Total Trials
5
Recruiting
0
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 1 (1)
Trial Status
Active Not Recruiting2
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03168737Phase 1Active Not Recruiting
18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
NCT07443761Active Not Recruiting
Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital.
NCT05523154Not ApplicableTerminated
"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures
NCT04716166Not ApplicableCompleted
Incentive Spirometry and Upper Abdominal Laparoscopic Surgery
NCT02337465Not ApplicableCompleted
KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer
Showing all 5 trials